A slew of niche U.S. equities is showing a sharp divergence in 2026 top-line growth, with laser manufacturer nLIGHT (LASE.US) and digital marketing firm QuinStreet (QNME.US) posting record quarterly revenues, while biotech players continue to burn cash to fund late-stage trials.

QuinStreet reported fiscal fourth-quarter revenue of $373.9 million, a 43% jump, fueled in part by its $115 million acquisition of HomeBuddy. nLIGHT similarly capitalized on defense and advanced manufacturing demand, logging $82.6 million in second-quarter sales.

Biotech remains a waiting game. Nektar Therapeutics (NKTR.US) posted a $40.6 million net loss on just $10.1 million in second-quarter revenue. Yet, with a cash position exceeding $1 billion, the company has a liquidity runway through 2028 as it advances its phase 3 eczema treatments.

In the broader industrials and components space, Comfort Systems USA (FIX.US) continues to scale its mechanical and electrical building systems networks. Display driver supplier Himax Technologies (HIMX.US) is leaning into automotive and AR/VR display controllers to offset broader semiconductor cyclicality.

Consumer and specialized portfolios are also seeing shifting capital. Latin American bottling and retail giant Fomento Económico Mexicano (FIGG.US) maintains its aggressive expansion of the OXXO franchise. Meanwhile, the SPDR S&P Kensho Smart Mobility ETF (SPSK.US) tracks autonomous driving and drone innovations, though thematic funds continue to face tightening liquidity environments.

Rounding out the diverse cohort, marketing automation software provider Klaviyo (KVYO.US), biopharma developer Belite Bio (BLTE.US), and precious metals miner Endeavour Silver Corp. (EXK.US) highlight the scattered nature of current market allocations, where underlying operational cash flow increasingly trumps speculative upside.